Boston, MA -- (SBWIRE) -- 04/24/2017 -- The global VTE therapeutics market is expected to benefit from the growing incidence of VTE worldwide. According to the CDC, every year around 0.9 million individuals are affected by VTE in the US and 60,000 to 100,000 individuals in the US die of VTE. Further, the presence of high unmet medical needs is expected to fuel the market growth. For instance, according to the CDC approximately 50% of individuals with VTE will have long-term complications, and 33% of individuals will have a recurrence within ten years.

Technavio's analysts forecast the global venous thromboembolism therapeutic market to grow at a CAGR of 6.40% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global venous thromboembolism therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of VTE products in the following drug classes.

Get More Details on this Report and a Full Table of Contents at Global Venous Thromboembolism Therapeutics Market 2017-2021

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global Venous Thromboembolism Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-Bayer HealthCare
-BMS
-Boehringer Ingelheim
-Daiichi Sankyo
-Johnson & Johnson
-Sanofi

Other prominent vendors

-Altor Bioscience
-Armetheon
-Aspen Pharma
-BioInvent International
-eXIthera Pharmaceuticals
-Gamma Therapeutics
-GlycoMimetics
-Green Cross
-Isis Pharmaceutical
-Leo Pharma
-Pfizer
-Portola Pharmaceuticals
-ThromboGenics

Market driver

-Increasing surgical procedures such as hip and knee replacements.
-For a full, detailed list, view our report

Market challenge

-Presence of alternatives such as thrombectomy and percutaneous techniques.
-For a full, detailed list, view our report

Market trend

-Development of drugs for new indications.
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2021 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: Bayer HealthCare, BMS, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Sanofi, Altor Bioscience, Armetheon, Aspen Pharma, BioInvent International, eXIthera Pharmaceuticals, Gamma Therapeutics, GlycoMimetics, Green Cross, Isis Pharmaceutical, Leo Pharma, Pfizer, Portola Pharmaceuticals, ThromboGenics

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-Venous Thromboembolism Global Clinical Trials Review, H2, 2016
-Thromboembolism Global Clinical Trials Review, H2, 2016
-Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth
-Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way
-Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market